LENZ Therapeutics August 2024 Investor Presentation

LENZ Therapeutics presents LNZ100, an aceclidine eye drop in development for presbyopia treatment with an NDA submitted in August 2024. The company projects FDA approval by mid-2025 and potential launch in the second half of 2025, targeting the $3B+ presbyopia market with 128M potential US patients. Phase 3 CLARITY 2 data show rapid onset, 10-hour duration, and near-universal response with 95% of participants achieving at least 2-line vision improvement.